Hyperlipidemia drugs Flashcards
cholesterol drug classes that affect exogenous pathway?
bile acid resins
transport inhibitors
cholesterol drug classes that affect endogenous pathway?
statins
fibric acid
acid- niacin
Bile acid resin drugs?
cholestyramine
colestipol
cholestyramine/colestipol MOA
bind negatively-charged bile acids in small intestine-forming insoluble complex excreted in feces
loss of bile acids leads to increase in LDL uptake receptors–>reduced plasma cholesterol
cholestyramine/colestipol TOX
increase TG levels in first few weeks
bad taste-like drinking sand
bloating
constipation/steatorrhea, anal leakage/fissures
impairment of other drug and fat soluble vitamin absorption
decrease LDL, slight increase of HDL, TG
Ezetimibe MOA
class: transport inhibitor
prevent cholesterol reabsorbtion at small intestine brush border
additive decrease in LDL when used with statins
little effect on HDL/TG
Ezetimibe TOX
Rare hepatic toxicity
drug interaction with cyclosporine
elevated transaminases
HMG CoA reductase (statins) MOA
inhibit HMG CoA reductase which catalyzes the conversion of acetyl CoA to melvonic acid
liver increases LDL receptors in response to low hepatic cholesterol causing increased reuptake
anti-inflammatory by reducing c reactive protein
HMG CoA reductase (statins) Uses
preferred lipid lowering drug
decrease LDL. TG, increase HDL
HMG CoA reductase (statins) TOX
hepatotoxicity-check liver enzymes
rhabdomyolysis- myopathy rare but life threatening
contraindicated with CYP450 inhibitors
deciding between older and newer statins?
older- cheaper, safer, more reliable
newer- more potent and efficacious, decrease LDL with smaller dose to minimize SEs
Niacin MOA
inhibition of VLDL secretion into circulation
inhibits lipolysis in adipose tissue
Niacin USE
most effective drug for increasing HDL
reduction in LDL and TG
Niacin TOX
only acid form is active- need to check vitamin OTC intense flushing and pruritis nausea, abd pain hyperuricemia hyperglycemia hepatotoxicity
Fibrates?
GEMFIBROZIL
CLOFIBRATE
bezafibrate
fenofibrate